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Abstract
Purpose The Patient Roles and Responsibilities Scale (PRRS) was developed to enable a broader evaluation of the impact 
of cancer and cancer treatment, measuring ‘real world’ roles and responsibilities such as caring for others and financial and 
employment responsibilities. Here, we report the development and initial validation.
Methods The 29-item PRRS was developed from the thematic analysis of two interview studies with cancer patients and 
caregivers. In the evaluation study, participants completed the PRRS alongside the Social Difficulties Inventory (SDI), the 
main criterion measure for concurrent validity, and the Functional Assessment of Cancer Therapy - General and WHO Qual-
ity of Life-BREF (WHOQOL-BREF) for additional convergent validity data. Questionnaires were completed at baseline, 
7-days (PRRS only) and 2 months. Demographic data and patient characteristics were collected at baseline.
Results One hundred and thirty-five patients with stage III/IV breast, lung or gynaecological cancer or melanoma completed 
the PRRS at least once. Five items performed poorly and were removed from the scale. The final 16 core items selected 
comprised 3 dimensions: family well-being, responsibilities and social life, and financial well-being, identified in principal 
component analysis, accounting for 61.5% of total variance. Missing data (0.6%) and floor/ceiling effects were low (0%/1.5%). 
Cronbach’s alpha was 0.9 for the PRRS-16; 0.79–0.87 for the subscales. PRRS showed good test–retest reliability (ICC-0.86), 
sensitivity to change and the predicted pattern of correlation with validation measures r = |0.65–0.77|. The standalone 7-item 
jobs and careers subscale requires further validation.
Conclusions Initial evaluation shows that the PRRS is psychometrically robust with potential to inform the evaluation of 
new treatments in clinical trials and real-world studies.
Keywords Cancer · Outcome measures · Psychometric performance · Validation · Questionnaire development
Background
More patients with cancer are living longer due in part 
to advances in molecular biology and the development of 
novel-targeted therapies [1]. There is growing recognition 
that assessment of the quality of this extended survival is 
important, namely how broader aspects of patients’ lives 
are managed and affected. Quality of survival (QoS) looks 
beyond traditional endpoints of survival times, response 
and adverse events towards an understanding of the longer 
term patient experience. Topics include emotional con-
cerns, financial burdens and impacts on role functioning 
[2]. Despite the extended survival benefits, associated 
side-effects from novel treatments can impact on a patient’s 
ability to live a ‘normal’ life. With maintenance therapy, 
patients may face a trade-off between the putative extension 
and quality of that survival [3]. Uncertainties about likely 
survival benefit can leave patients and their families unable, 
or unwilling to make plans for the future [4].
Well-validated measures of financial and social distress 
exist (Comprehensive Score for Financial Toxicity [5, 6] 
and Social Difficulties Inventory [7, 8]), but there are cur-
rently no such measures that capture fully all aspects of the 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1113 6-018-1940-2) contains 
supplementary material, which is available to authorized users.
 * Valerie Shilling 
 v.m.shilling@sussex.ac.uk
1 Sussex Health Outcomes Research and Education in Cancer 
(SHORE-C), Brighton and Sussex Medical School, 
University of Sussex, Falmer, Brighton, UK
2 Department of Medical Social Sciences, Northwestern 
University Feinberg School of Medicine, Chicago, IL, USA
 Quality of Life Research
1 3
concept of QoS. The Quality of Life in Adult Cancer Survi-
vors (QLACS) measure covers a number of these areas e.g. 
financial problems, family-related distress, but was devel-
oped specifically for use with long-term cancer survivors, 
defined by the authors as greater than five years from diag-
nosis [9]. Although the European Organisation for Research 
and Treatment of Cancer (EORTC) and the National Institute 
of Health (NIH) funded Patient Reported Outcomes Meas-
urement Information System (PROMIS) initiatives have 
developed role functioning item banks for use in computer 
adaptive testing [10, 11], the impact of disease and treatment 
on roles and responsibilities is generally underrepresented in 
health-related patient reported outcome measures (PROMs). 
This is a serious oversight as many patients have caregiving 
responsibilities, for children, grandchildren, parents, part-
ners or even pets. Qualitative studies demonstrate that these 
types of roles and responsibilities outside of work are a sig-
nificant part of patients’ lives, which cancer and its treatment 
can seriously impinge upon [12–16]. As role functioning 
issues are somewhat poorly described, many patients feel 
that information on how to cope at home is inadequate [17].
Our recent systematic reviews of PROMs currently in use 
identified areas of concern that are insufficiently researched, 
namely family, financial and occupational circumstances 
[18, 19]. Furthermore, QoS is not a static concept; it 
includes recognition that the relative importance of differ-
ent dimensions will change across the disease trajectory. As 
such we designed the PROACT programme of work (Patient 
Reported Outcomes impact of Age and Carer role demands 
associated with Treatment) recognising that patients and 
their families are continually adjusting to a fluid situation 
whilst trying to maintain their ‘real world’ roles and respon-
sibilities beyond cancer, such as caregiving responsibilities 
for a spouse or children/grandchildren, jobs and financial 
responsibilities [4].
Overview
PROACT is a multi-phase project, informed by the QoS 
conceptual framework, with the primary aim to develop 
and evaluate two self-report measures; one for patients and 
another for informal caregivers to assess comprehensively 
broader impacts of disease and treatment. The measures 
have been developed to be compatible with the Functional 
Assessment of Chronic Illness Therapy (FACIT) measure-
ment system and are intended to benefit future patients and 
caregivers by capturing these wider impacts of cancer and its 
treatment during the evaluation of new treatments in clinical 
trials and could be used to aid clinical conversations around 
treatment and intervention.
To develop the PROACT measures, we conducted two sys-
tematic reviews [18, 19] to inform our understanding of the 
content and psychometric properties of measures currently 
being used, and to identify gaps in relevant domains. Develop-
ment of the two PROACT measures then followed three phases 
of scale development: item generation (study 1), item-reduc-
tion and scale construction (study 2) and initial scale evalua-
tion and validation (study 3). Because the topics covered in the 
scale are not related to specific issues such as treatment side 
effects, rather to the broader impact such as time off work, it is 
intended that it will be useful for all groups of cancer patients. 
The development studies were conducted with patients with 
stage III/IV cancer and the person they nominated as their 
main source of support. However, the measures are intended 
to be suitable for all stages of cancer and are currently being 
validated in early stage disease. This paper reports the devel-
opment and evaluation of the multi-dimensional Patient Roles 
and Responsibilities Scale (PRRS). The Caregiver Roles and 
Responsibilities Scale (CRRS) was developed concurrently 
and is reported elsewhere.
Ethics statement
Studies received ethics approval from London Queen Square 
Research Ethics Committee (ref: 15/LO/1323 Studies 1 and 
2; ref: 16/LO/1125 Study 3). Signed informed consent was 
obtained from all participants.
Eligibility criteria
Inclusion/exclusion criteria were similar across all three 
studies. Eligible patients had advanced (stage III/IV) mela-
noma, lung or gynaecological cancer, with a requirement 
that they could nominate an informal caregiver also will-
ing to take part. Both patients and caregivers were required 
to be over 18 years of age, have capacity to give informed 
consent and be able to read and speak English. Those who 
were currently inpatients or acutely distressed for any reason 
were excluded. In studies 2 and 3, we expanded the patient 
population to include women with breast cancer. The cancer 
types were selected to represent a range of potential cancer 
experiences in order that the measure might be sufficiently 
generic for other tumour sites. Study 3 did not require that 
both patient and caregiver consent to the study; either party 
could participate alone.
Scale development: methods and results
Study 1: item generation
We conducted in-depth qualitative interviews with 24 
patients with advanced cancer and separate interviews 
with their nominated informal caregivers (N = 23) about 
the impact of extended cancer survival on broader aspects 
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of life and well-being (see Supplementary File S1 for par-
ticipant demographics). Topic guides were informed by our 
earlier systematic reviews [18, 19] and through discussion 
with advisors with a lived experience of cancer or who were 
supporting someone with cancer. Participants were first 
invited to generate and speak freely about topics important 
to their well-being and if and how these areas of life had 
been impacted by their/their loved one’s cancer diagnosis 
and treatment. Further discussion was prompted (where nec-
essary) around topics such as family life, relationships, lei-
sure and social activities, employment and finances, physical 
and emotional health. Interviews were recorded (38.5 h of 
recorded data) and transcribed verbatim.
A thematic framework was developed from an initial pro-
cess of open coding and tested iteratively as new data were 
collected. Thematic analysis identified 20 themes and 33 
sub-themes from which a long list of 179 potential items 
was generated for the patient scale. These were reviewed for 
relevance and redundancy by the authors before 44 potential 
items were reviewed by our panel of advisors with lived 
experience. Consensus decisions on whether an item was 
retained or not were made through discussion informed by 
the thematic analysis of the interviews. Items were evalu-
ated based on the relative importance the content appeared 
to have across interviews both in terms of the frequency 
with which the topic was discussed by participants and the 
significance attached to it.
Thirty items were retained for evaluation in Study 2. 
Where appropriate items already existed in the FACIT sys-
tem, these validated items were used, rather than generating 
new ones. This included three items from the FACIT Com-
prehensive Score for Finacial Toxicity (COST) measure [5].
Interviews and thematic analysis were conducted by VS/
RS. The long list of potential items was generated by VS/
RS/VJ/LF and reviewed and reduced through discussion 
between VS/RS/VJ/LF and our panel of five advisors with 
lived experience.
Study 2: item reduction and scale construction
Cognitive interview techniques were employed to ‘test’ the 
potential questionnaire items. The processes participants 
applied when answering were explored, enabling us to check 
that the items were being understood as intended and con-
sistently by different people, for example [20]. Cognitive 
interviews were conducted with a new cohort of 20 patients 
and informal caregivers using a mixture of the ‘think aloud’ 
technique (where participants verbalise the thought pro-
cesses they go through in answering a questionnaire item) 
and specific probes around comprehension, retrieval, judge-
ment and response options to assess each of the potential 
scale items. Example probes included: What does that ques-
tion mean to you, in your own words? What factors did you 
consider when you were deciding on your answer? Were you 
able to match the answer you wanted to give to one of the 
choices we’ve given you? Items were also discussed in terms 
of acceptability, relevance, redundancy and importance. Par-
ticipants were also asked to identify missing topics. See Sup-
plementary File S1 for participant demographics.
Scale items were revised, added and removed in an itera-
tive fashion through the course of the study. Through this 
process 51 changes were made to the scale including 44 
wording revisions, 4 deletions and 3 additions, resulting in a 
29-item scale grouped conceptually into items around family 
and home life (N = 13), financial well-being (N = 8) and jobs 
and careers (N = 8).
As with study 1, interviews and initial analysis were 
conducted by VS/RS with any changes to the scale in the 
course of the study agreed by consensus between VS/RS/
VJ/LJ after discussion of the interview content. Final scales 
were reviewed and agreed by VS/RS/VJ/LF and our panel 
of five advisors with lived experience.
Initial evaluation and validation: study 3
Methods
Population and procedure Participants were recruited from 
11 sites in the United Kingdom, stratified by age group (≤ 50, 
51–65, ≥ 66 years) and tumour site (breast, gynaecological, 
lung, melanoma). All participants had stage III/IV cancer. 
Participants completed questionnaires at home either on 
paper or online, whichever their preference. Demographics 
and the full validation pack were completed at baseline, the 
PRRS was completed alone after 7 days (for test–retest reli-
ability) and the full battery completed again after 2 months 
(for sensitivity to change).
Measures Participants completed the PRRS alongside the 
FACT-G, the SDI and the WHOQOL-BREF and provided 
basic demographic information such as age, employment 
status, level of education, relationship status and caregiving 
responsibilities along with information regarding diagnosis 
and treatment.
The PRRS The PRRS as completed in the validation study 
comprised 29 items: 21 core items formatted for the FACIT 
measurement system (responses as item applies to the past 
7 days, 5 response options ranging from not at all—very 
much) and 1 binary response item on whether the partici-
pant has stopped work due to illness. A standalone scale, 
jobs and careers comprising 7 items is completed only by 
participants currently in paid employment (including those 
on sick leave). Negatively worded items were reverse scored 
so that a higher score corresponds to better quality of life. 
Where missing data occurred, total scores were prorated as 
long as more than half of the scale items were completed.
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The SDI [7] The SDI is a 21-item questionnaire developed 
for use in oncology practice. It covers a range of difficulties 
that might be experienced by patients in their everyday life 
and includes an everyday living subscale; money matters 
subscale and self and others subscale. There are five stan-
dalone items about difficulties around: sex, plans to have 
a family, living conditions, holidays and ‘other’. Items are 
rated on a 4-point scale of no difficulty—very much (scored 
0–3). For this analysis, we use the SD-16 scale which 
excludes the standalone items. The SD-16 generates a total 
score with range 0–44 (4 items are scored 0–2) with higher 
scores indicating greater social difficulty and also provides 
an established cut-off point to categorise patients as dis-
tressed/not distressed with the threshold set at SD-16 ≥ 10 
[21].
The FACT-G [22] The FACT-G is a well-validated meas-
ure of health-related quality of life with 27 items comprised 
of four subscales: physical well-being (7 items), social well-
being (7 items), emotional well-being (6 items) and func-
tional well-being (7 items). Items are rated on a 5-point scale 
of not at all—very much (scored 0–4). Total score range is 
0–108 with higher scores indicating higher quality of life.
Item GF7 “I am content with the quality of life right now” 
is used as the anchor variable to assess PRRS sensitivity to 
change.
The WHOQOL-BREF [23] The WHOQOL-BREF has 
26-items producing a quality of life profile with four domain 
scores (physical health, psychological health, social relation-
ships and environment) and two individually scored items 
about an individual’s overall perception of quality of life and 
health. Each item is rated on a 5-point scale (scored 1–5). 
The four domain scores are scaled in a positive direction 
with higher scores indicating a higher quality of life.
Data analysis
Analyses were conducted using the Statistical Package for 
Social Sciences (IBM SPSS; version 23). Missing data from 
PRRS were managed by pro-rating total and were appropri-
ate subscale scores. Missing data from other questionnaires 
were managed as per the specific instrument guidance. We 
used guidelines from the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) [24, 25] and 
COSMIN (Consensus-based Standards for the selection of 
health Measurement Instruments) [26] in the development 
and evaluation of this measure.
Content validity
The PRRS was developed through extensive qualitative 
interviews in studies 1 and 2 and through collaboration 
with advisors with lived experience of cancer or caring for 
someone with cancer; no further content validation was 
undertaken.
Acceptability and precision
Acceptability was assessed by consideration of the amount 
of missing data overall and per item and the time to com-
plete the scale. 15% missing data were set as the acceptable 
threshold for individual items.
Precision was assessed on a number of dimensions. Indi-
vidual items with floor/ceiling effects > 70% were considered 
for removal as were those with a z-score of skewness >ǀ4ǀ. 
Individual items were also evaluated in terms of the pattern 
of correlation (items failing to show a pattern of correlation 
above 0.3 with multiple items or correlation with another 
item at ≥ 0.8 were reviewed) and of corrected item-total cor-
relation (items with CITC < 0.3 were reviewed). Items that 
performed poorly on any of these criteria were considered 
for removal from the scale.
Exploratory factor analysis
Principal components analysis with oblique rotation was 
performed to identify underlying factors. Bartlett’s test of 
sphericity and the Kaiser–Meyer–Olkin (KMO) value were 
checked to confirm that the data were suitable for factor 
analysis. We applied the criterion of Eigenvalue > 1.0 and 
also examined the scree plot to determine the number of 
factors retained. Items were included in the factor on which 
they loaded highest (minimum accepted 0.4). The unidimen-
sionality of subscales was assessed with corrected item-total 
correlations (r ≥ 0.3 considered acceptable) and reliability 
with Cronbach’s alpha. Missing values were managed using 
listwise deletion. Finally, we assessed whether the solution 
made conceptual and practical sense.
Internal consistency
Internal consistency was assessed using Cronbach’s alpha 
(for good internal consistency we would expect α ≥ 0.70).
Criterion and convergent validity
Criterion validity was assessed by correlation with a com-
monly used legacy measure of the same concept, the SDI. 
We predicted a strong, negative correlation (r > − 0.7). Con-
vergent validity was further evaluated by correlating with 
other similar measures. We predicted a moderate to strong 
positive correlation (0.5 < r < 0.7) between PRRS scores and 
the FACT-G and WHOQOL-BREF.
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Test–retest reliability
Test–retest reliability was assessed by comparing responses 
at baseline and at 7 days. Intraclass Correlations (ICCs; 
two-way random, absolute agreement) were calculated for 
total PRRS scores and sub-scale totals. An ICC > 0.7 is con-
sidered adequate, > 0.9, excellent. Weighted kappa scores 
(using linear weighting) were calculated for individual 
items; a score of κ ≥ 0.4 was considered acceptable, κ ≥ 0.6, 
good.
Sensitivity to change
PRRS change scores were calculated (T1–T3). Patients 
were categorised as improved, worsened or unchanged 
based on responses to the anchor question ‘I am content 
with the quality of my life right now’. Paired t tests were 
used to determine if PRRS change within a group was sig-
nificantly different from zero. Spearman correlation coef-
ficients were calculated to explore the relationship between 
changes on the PRRS, anchor variable and other validation 
measures. We would expect moderate positive correlation 
(0.3 < r < 0.5) between change on the PRRS and the FACT-
G and WHOQOL-BREF and moderate negative correlation 
between change on the PRRS and SDI (− 0.3 < r < − 0.5).
Results
Participants
One hundred and forty-three patients consented to take 
part, 135 completed baseline (37 breast, 35 gynaecological, 
33 lung, 30 melanoma), 128 completed T2 and 118 com-
pleted T3. At baseline age ranged from 33 to 85 (median 
61 years), 77% were female. See Fig. 1 for full details of 
patients approached, consented and completed question-
naires at each time point, along with reasons for decline/
drop out and Table 1 for key participant characteristics.
Acceptability of PRRS
Missing data rate for the PRRS was extremely low, 0.6% at 
baseline, 0.5% at Time 2 and 0.6% at Time 3. Missing data 
were distributed across 10 of the 28 Likert-scale items at 
baseline, 7 of the 28 items at Time 2 and 10 at Time 3 with 
no single item having more than 4 missing responses. The 
highest rate of missing data for a single item at any time 
point was 7% (an employment question with 26/28 possible 
responses); for core questions with the larger sample, the 
highest rate of missing data for a single item at any time 
point was 3% (threshold for investigation was > 15% miss-
ing data).
At baseline, 60 participants completed questionnaires 
online, 75 completed on paper but only 61 recorded 
the time taken to complete the PRRS. Time to complete 
online ranged from 1.87 to 14.05  min with 1 extreme 
outlier at 34.78 min (mean excluding outlier = 4.71 min, 
SD = 2.21 min). On paper, time to complete ranged from 2 
to 20 min with one extreme outlier at 30 min (mean exclud-
ing outlier = 8.52 min, SD = 4.22 min).
Remaining analyses and results are presented separately 
for the PRRS core items and the jobs and career subscale, 
which is only completed by participants currently in paid 
employment.
PRRS core items
Precision and item reduction
Five items had an unacceptably low level of correlation with 
other items and low (< 0.3) corrected item-total correlations 
in reliability analysis. In addition, one of these did not meet 
the measure of sampling adequacy (set at 0.7). These five 
underperforming items were removed from further analysis. 
Four of the retained items had z-scores of skewness >ǀ4ǀ; 
however, their performance in terms of relationship to other 
items corrected item-total correlation and/or conceptual sig-
nificance to the measure ensured their retention at this stage. 
No item correlated r > 0.8 with any other item.
None of the remaining individual items had missing 
data > 15% or floor effects exceeding 70% (range 1.5–41.5%, 
on 12/16 items less than 20% of responses were the mini-
mum ‘0’ response option). One item showed above threshold 
ceiling effects (74% ‘my family have to help me financially’, 
note this item is reverse scored; a response of  ‘not at all’ 
receives a score of ‘4’). Scores of maximum ‘4’ ranged from 
7.4 to 74%; 4/16 items had less than 20% of responses at 
maximum ‘4’.
Total scores on the modified PRRS Core-16 (N = 135) 
ranged from 10 to 64 (possible range 0–64), with mean, 
39.20, SD 13.04, with skewness = − 0.08 (SE = 0.204). No 
participants had minimum scores. 2 participants (1.5%) had 
maximum scores (threshold for ceiling effects set at 15%).
Exploratory factor analysis
Following listwise deletion based on all variables, N = 130. 
Bartlett’s test of sphericity was significant at < 0.0001 and 
the KMO value was 0.850 confirming that the data were 
suitable for factor analysis. MSA for all variables was > 0.7 
suggesting adequate communality with other variables. 3 
Eigenvalues were greater than 1 explaining 40.8, 10.4 and 
10.3% of variance respectively (total variance explained 
61.5%). The scree plot (Fig. 2) confirmed that 3 factors 
should be retained corresponding to family well-being 
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(Factor 1), financial well-being (Factor 2) and responsibili-
ties and social life (Factor 3). All items except one loaded 
clearly on one factor. One item (PL9: “The way I see myself 
within the family has changed because of my illness”) cross 
loaded on Factor 1 (0.433) and Factor 3 (− 0.428). This item 
was retained for the family well-being subscale. The items 
and their loadings are shown in Table 2.
Reliability analyses were conducted for the three 
potential subscales using only the final items within 
the subscales. Cronbach’s α for family well-being was 
Baseline data completed = 135
Inial Expression of Interest = 237
(Before receiving parcipant
informaon sheet)
Verbal consent having read
parcipant informaon sheet and
asked quesons =160 pts
Wrien consent returned to site = 143
T2 data completed = 128
T3 data completed = 118
N Lost to follow up: 12*
Death – 4
Illness – 2
Lost to follow up – 4
Withdrew without reason - 2
*2 Parcipants missing at T2 re-joined at T3
N Lost to follow up: 7
Distressed -1
Illness – 2
Lost to follow up – 1
Skipped or delayed me point - 3
N Lost to follow up: 8
Illness – 3
Lost to follow up – 4
Withdrew without reason - 1
Lost to follow up: 17
Death – 1
Illness – 5
Lost to follow up – 10
Not wanng to focus on disease – 1
Pts Decline or lost to follow up: 77
Busy/Time pressures/Overwhelmed - 24
Death – 4
Illness – 6
Ineligible - 1
Lost to follow up – 24
Not interested – 10
Not interested but cg took part - 3
Not wanng to focus on disease – 5
Lung = 80Breast = 58 Gyn = 58 Melanoma = 41
Lung = 31Breast = 36 Gyn = 33 Melanoma = 28
Lung = 33Breast = 37 Gyn = 35 Melanoma = 30
Lung = 34Breast = 42 Gyn = 35 Melanoma = 32
Lung = 41Breast = 49 Gyn = 37 Melanoma = 33
Breast = 33 Gyn = 32 Lung = 24 Melanoma = 29
Fig. 1  Flow of participants through study
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0.87 (N = 132, corrected item-total correlation range 
0.60–0.76); for responsibilities and social life, 0.84 
(N = 133, CITC range 0.50–0.71) and for financial 
Table 1  Key patient 
 characteristicsa and PRRS total 
 scoresb
a Ethnicity is not included as 96% of the population identified as White British
b Total scores on final modified scale, post item reduction
N = 135 PRRS
(Mean ± SD)
Univariate P
Cancer type
 Breast 37 (27.5%) 36.00 ± 14.38 0.060
 Gynaecological 35 (26%) 40.07 ± 12.54
 Lung 33 (24.5%) 37.36 ± 11.28
 Melanoma 30 (22%) 44.13 ± 12.71
Time since diagnosis
 <1 year 40 (30%) 36.61 ± 12.44 0.329
 1–2 years 21 (15%) 40.48 ± 15.22
 >2 years 74 (55%) 40.23 ± 12.69
On treatment (missing N = 22)
 Yes 76 (67%) 40.16 ± 12.74 0.445
 No 37 (33%) 38.14 ± 13.99
Age group 0.003
Post hoc comparison (Bonferroni) old vs 
young p = .003
 ≤ 50 34 (25%) 34.54 ± 11.73
 51–65 55 (41%) 38.03 ± 12.68
 ≥ 66 46 (34%) 44.03 ± 13.07
Sex
 Female 104 (77%) 38.25 ± 13.52 0.121
 Male 31 (23%) 42.39 ± 10.90
Relationship status
 Partner 105 (78%) 39.39 ± 13.03 0.754
 No partner 30 (22%) 38.53 ± 13.28
Employment status
 Retired 70 (52%) 42.60 ± 12.52 0.001
Bonferroni retired v not employed p = .001 Employed/self employed 38 (28%) 38.26 ± 12.37
 Not in paid employment 27 (20%) 31.69 ± 12.33
Gave up work due to illness
 Yes 53 (39%) 32.34 ± 10.76 < 0.0001
 No 82 (61%) 43.63 ± 12.51
Education (missing N = 2)
 Secondary 51 (38%) 40.91 ± 13.71 0.236
 Further 17 (13%) 35.59 ± 10.48
 University 32 (24%) 35.78 ± 12.55
 Professional qualifications 33 (25%) 41.52 ± 13.46
Caregiving responsibilities
 Yes 88 (65%) 37.74 ± 12.79 0.076
 No 47 (35%) 41.92 ± 13.21
Caregiving responsibilities (for 
children/grandchildren only)
0.413
 Yes 40 (30%) 37.78 ± 14.03
 No 95 (70%) 39.79 ± 12.63
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Fig. 2  Scree plot
Table 2  Item factor loading
Item Factor 1 Factor 2 Factor 3
PL1 My illness interferes with performing my responsibilities at home (e.g. cooking, cleaning, gardening, 
DIY)
− 0.790
PL3 I am less able to fulfil my caregiving responsibilities (e.g. looking after children, grandchildren, another 
adult, pets)
− 0.892
PL4 I have less patience for my caregiving responsibilities (e.g. looking after children, grandchildren, another 
adult, pets)
− 0.674
PL5 I feel sad that my illness forces me to miss out on doing things with my children and/or other family 
members
− 0.681
PL6 I worry about the impact of my illness on my partner (or the person who is my main support) 0.803
PL7 I worry about the impact of my illness on my children and/or other family members 0.801
PL8 I worry about the impact of my illness on people that I normally provide support to (e.g. friends, neigh-
bours, parents and/or grandchildren)
0.774
PL9 The way I see myself within the family has changed because of my illness 0.433 − 0.428
PL11 I worry how my family will cope in the future 0.872
PL13 I socialise less because of my illness − 0.653
FT3 I worry about the financial problems I will have in the future as a result of my illness or treatment 0.561
FT11 I feel in control of my financial situation 0.500
PF3 My family gives up things because of the financial impact of my illness 0.618
PF4 My family have to help me financially 0.798
PF5 The additional costs of my illness are more than I thought they would be (e.g. travel and parking, heating, 
healthy eating, supplements, non-prescription medication, paying for help at home)
0.686
PF6 I have difficulty meeting the additional costs of my illness 0.874
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well-being 0.79 (N = 135, CITC range 0.47–0.71). Inter-
item and inter-subscale correlations are shown in Table 3.
Internal consistency
Cronbach’s α for the modified PRRS total score at baseline 
(N = 131, listwise deletion based on all variables) was 0.90 
(CITC range 0.43–0.72); at T2 (N = 124) α = 0.90 (CITC 
range 0.37–0.73); and at T3 (N = 112) α = 0.91 (CITC range 
0.43–0.76). In no case was α increased by the deletion of 
an item.
Criterion and convergent validity
As predicted, total scores on the PRRS correlated strongly 
and negatively with scores on the SDI (N = 135, r = − 0.77). 
We did not find the floor effects reported elsewhere for 
SD-16 scores [27]; however, the distribution was skewed in 
that direction. As a precautionary measure, we categorised 
participants as distressed or not distressed based on a cut-
off threshold of ≥ 10/44 as recommended by the instrument 
authors [21]. 58 (43%) participants were categorised as dis-
tressed. We then used this dichotomous variable in a point-
biserial correlation with total PRRS score. As expected, 
the correlation was strong; N = 135, r = − 0.65. Correla-
tions between the PRRS subscales and most appropriately 
matched subscales of the SDI were also moderate to strong: 
PRRS responsibilities and social life with SDI everyday liv-
ing r = − 0.71; PRRS financial well-being with SDI money 
matters r = − 0.65; PRRS family well-being with SDI self 
and others r = − 0.52. PRRS scores showed the predicted 
correlations with FACT-G (N = 135, r = 0.65) and WHO-
QOL-BREF (N = 135, r = 0.65).
Test–retest reliability
The median number of days between baseline and T2 was 
8 (mode 7, range 3–21). Total PRRS scores showed good 
test–retest reliability (two-way random, absolute agree-
ment) (N = 128, ICC = 0.86, 95% CI 0.80–0.90) as did the 
three subscales responsibilities and social life (N = 128, 
ICC = 0.83, 95% CI 0.77–0.88), family well-being (N = 128, 
ICC = 0.77, 95% CI 0.68–0.83) and financial well-being 
(N = 128, ICC = 0.86, 95% CI 0.81–0.90). Weighted kappa 
scores for individual items were all in the acceptable range 
(κ ≥ 0.4) and ranged from 0.44 to 0.63.
Sensitivity to change
The median number of days between baseline and T3 was 66 
(mode 60, range 56–117). Table 4 shows change over time 
in the anchor variable GF7 (I am content with the quality of 
my life right now). 47.5% of participants reported no change, 
26.25% of participants reported an improvement by one or 
more points and the same proportion reported decline by 
one or more points. Participants whose GF7 score improved 
showed significant improvement in their PRRS scores 
(p = .008), those reporting decline on GF7 showed signifi-
cant decline on PRRS (p = .001). As predicted, PRRS scores 
did not change significantly for those participants reporting 
no change on GF7 (p = .891). The groups do not differ at 
Table 3  Inter-item correlations and correlation between subscale scores
Subscale Mean (SD)
Range
Inter-item cor-
relation range
Correlations between subscale scores
Family well-being Responsibilities 
and social life
Financial 
well-
being
Family well-being (5 items, possible score 0–20) 8.38 (5.57)
0–20
0.479–0.670
N = 132
1.00
Responsibilities and social life (5 items, possible score 0–20) 12.85 (5.12)
0–20
0.324–0.665
N = 133
0.563
N = 135
1.00
Financial well-being (6 items, possible score 0–24) 17.97 (5.01)
5–24
0.211–0.610
N = 135
0.544
N = 135
0.493
N = 135
1.00
Table 4  PRRS change by 
change on anchor variable GF7 
(I am content with the quality of 
my life right now)
a Mean change score/SD mean baseline score
I am content with the quality of my 
life right now
N Baseline PRRS 
mean (SD)
Mean PRRS 
change (SD)
p Effect  sizea
Improved by one point or more 31 39.21 (13.87) − 3.88 (7.58) 0.008 − 0.28
Unchanged 56 39.52 (13.67) − 0.12 (6.72) 0.891 − 0.01
Worsened by one point or more 31 40.58 (12.10) 4.55 (6.79) 0.001 0.38
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baseline. PRRS change scores correlated significantly with 
change on the anchor variable (r = 0.42) and with change 
on other measures: FACTG (r = 0.48) SDI (r = − 0.42) and 
WHOQOL-BREF (r = 0.32).
PRRS jobs and career subscale
The jobs and career subscale was completed by just 33, 30 
and 28 patients (31, 29, 25 provided complete data) at the 
different time points, respectively; too few for reliability 
analyses. Table 5 shows baseline summary statistics for the 
items that make up the scale. The item PE3 had a particu-
larly weak pattern of correlation with other subscale items 
(N = 33, r = 0.03–0.32) and two items (PE3 and PE7) dem-
onstrated ceiling effects; however due to the small number 
of participants completing the scale, we will not eliminate 
items at this stage.
Discussion
We report the development and validation of the PRRS, a 
patient self-report measure of the impacts of cancer and 
treatment on family, financial and occupational roles and 
responsibilities. The format and structure are compatible 
with the FACIT measurement system. The scale was devel-
oped with advanced cancer patients and found to have very 
good reliability and validity in field testing. Although devel-
oped and validated on people with advanced cancer, the scale 
was developed with the intention to be sufficiently generic 
and appropriate for use in all stages of cancer. Indeed, due 
to the nature of the topics covered in the PRRS (i.e. family, 
finances, employment), there is potential for use in other 
chronic conditions. The scale is currently undergoing field 
testing with patients with early stage cancer. Extensive quali-
tative work to establish content validity would be required 
before any field testing in other chronic conditions would be 
possible. This should be a topic for further research.
The PRRS appears to be acceptable to participants both in 
terms of time to complete and the very low missing data rate 
in total and per item. Missing data on the final scale appear 
to be at random and are therefore assumed not to be indica-
tive of a problem with any particular item. No participants 
recorded minimum scores on the final scale and only 2/135 
recorded maximum scores.
Factor analysis of the Core-16 items revealed a three-
factor solution corresponding to three potential subscales: 
family well-being, financial well-being, and responsibilities 
and social life. All demonstrated good internal consistency 
as does the PRRS-16 total score. Future studies will seek 
to confirm the factor structure and factorial invariance. The 
PRRS-16 total score showed the predicted strength of cor-
relations with measures for criterion and convergent valid-
ity and good test–retest reliability. The scale demonstrated 
sensitivity to change; those patients showing improvement 
on the anchor variable showed significant improvement in 
PRRS scores, and those declining on the anchor variable 
showed significant decline in PRRS scores. Though signifi-
cant, the effect size in both groups was small to medium. 
The magnitude of the effect is likely related to our choice 
of anchor variable and that we set just one point shift as the 
threshold for change on the anchor. As reported elsewhere 
[28] the absolute PRRS change was greater in those report-
ing worsening on the anchor variable than those reporting 
improvement.
We believe that there is utility in a total score for the 
PRRS, particularly when the scale is being used as part of a 
clinical discussion for straightforward monitoring of global 
change over time and as a way to quickly flag patients who 
might be experiencing difficulties and for whom further dis-
cussion and investigation might be appropriate. That said, 
the subscale scores may provide useful indication of how 
Table 5  Baseline descriptive statistics for items on the jobs and career subscale (N = 33)
a Items are reverse scored
Item Missing 
data (%)
Mean ± SD Median/mode |z-score 
skew|
% floor (score 0) % ceiling 
(score 4)
PE2 I have reduced my working hours because of my 
 illnessa
0 2.06 ± 1.66 3.0/0 0.57 33.3 24.2
PE3 My working hours are flexible to accommodate my 
treatment and appointments
0 3.00 ± 1.44 4.0/4 2.97 12.1 57.6
PE4 I feel I am able to do my job as well as I would like 0 2.30 ± 1.45 3.0/3 1.39 21.2 21.2
PE5 I worry that my illness will impact my employment in 
the future (including return to work)a
0 1.64 ± 1.34 2.0/2 0.76 27.3 12.1
FT9 I am concerned about keeping my job and  incomea 0 1.79 ± 1.52 2.0/0 0.38 30.3 18.2
PE6 I feel that my illness has limited my  careera opportu-
nities
0 2.48 ± 1.77 3.0/4 1.43 30.3 48.5
PE7 I feel supported by my employer 6.06 3.39 ± 1.12 4.0/4 4.21 3.2 71.0
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different domains are impacted for different individuals, 
allowing for more tailored approach to supportive interven-
tions. Interpreting the profile of subscale scores rather than 
a total score is likely to be more appropriate and useful in 
some circumstances [29, 30].
We did not make a priori hypotheses on group differ-
ences on either the PRRS total score or scores on separate 
domains. We found that age was a significant factor with sig-
nificant post hoc contrasts between those over 65 years and 
those 50 years or younger. Those patients already retired had 
significantly higher scores than those not in paid employ-
ment (but not those currently working) and those who 
had been forced to give up work due to illness had signifi-
cantly lower scores than those who had not (either because 
they were not working or had continued to work). Scores 
for those who had caregiving responsibilities were lower 
than for those who did not, but not significantly so. A more 
nuanced exploration of the role of age and responsibilities 
to self and others is beyond the remit of this paper but will 
be presented elsewhere.
We indicated in the introduction that excellent, well-
validated measures such as the SDI [7, 8] and COST [5, 6] 
exist. We believe that the PRRS provides a useful scale with 
more comprehensive coverage. For example, the SDI is not 
intended to provide a full assessment of jobs and careers; 
likewise the COST was not developed to measure family 
function and responsibilities. The PRRS has been developed 
following FACIT convention with the intention that it will 
sit within the FACIT measurement system and can be used 
alongside the FACT-G and or/other FACIT measures to pro-
vide comprehensive assessment.
Limitations
The main limitation relates to sample size for the valida-
tion study, particularly the jobs and careers subscale. While 
we have sufficient participant numbers for the factor and 
reliability analysis of the core questionnaire items, we were 
unable to evaluate the jobs and careers subscale fully. A 
further validation study is currently underway to address 
this shortfall.
We chose to develop the measure in patients with stage 
III/IV cancer; the stimulus for the programme of research 
being the increase in numbers of people living with cancer 
as a chronic condition. We also developed the measures in 
a limited number of tumour groups which although chosen 
to ensure a spread of key patient characteristics such as age, 
inevitably resulted in some sampling bias. For example two 
of the four cancer sites (breast and gynaecology) recruited 
only females resulting in a disproportionate number of 
female participants (77%). We did not have access to per-
formance status scores for patients; this would be a useful 
group comparison in future research.
In any development study, choices are made regarding 
participant characteristics which limit the immediate gener-
alizability of the findings. However, the PROACT measures 
were developed with an intention to be sufficiently generic 
for application to all disease stages and tumour types. Fur-
ther validation will ensure that the measures are sufficiently 
generic for use in clinical trials and realworld studies.
Conclusion
The PRRS was developed to capture broad ‘real life’ impacts 
of cancer and its treatment and has potential use for both 
research and practice. For example, it may be used in the 
assessment of quality of life during the evaluation of new 
treatments in clinical trials and real world studies. It is 
potentially useful therefore to regulatory authorities scru-
tinising data from clinical trials and to policy makers when 
determining ‘costs’ of different treatments. The scale could 
also aid clinical conversations around treatment and inter-
vention, with a growing body of evidence demonstrating 
the value of using PROMs in this way [31–35]. This initial 
evaluation shows that the PRRS is psychometrically robust 
with potential to inform the evaluation of novel therapies and 
to help drive the development of ameliorative interventions 
for the enhancement of extended survivorship.
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